3.08 USD
-0.16 (-4.94%)
3.07 USD
-0.01 (-0.32%)
Taking everything into account, QNCX scores 1 out of 10 in our fundamental rating. QNCX was compared to 525 industry peers in the Biotechnology industry. The financial health of QNCX is average, but there are quite some concerns on its profitability. QNCX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year QNCX has reported negative net income.
- QNCX had a negative operating cash flow in the past year.
- In the past 5 years QNCX always reported negative net income.
- QNCX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -51.85%, QNCX is in line with its industry, outperforming 48.57% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -5380.45%, QNCX is doing worse than 81.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.85% | ||
| ROE | -5380.45% | ||
| ROIC | N/A |
ROA(3y)-39.35%
ROA(5y)-45.23%
ROE(3y)-92.25%
ROE(5y)-79.44%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- QNCX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- Compared to 1 year ago, QNCX has more shares outstanding
- Compared to 5 years ago, QNCX has more shares outstanding
- QNCX has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -5.89, we must say that QNCX is in the distress zone and has some risk of bankruptcy.
- QNCX has a worse Altman-Z score (-5.89) than 63.24% of its industry peers.
- There is no outstanding debt for QNCX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.89 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- QNCX has a Current Ratio of 1.12. This is a normal value and indicates that QNCX is financially healthy and should not expect problems in meeting its short term obligations.
- QNCX's Current ratio of 1.12 is on the low side compared to the rest of the industry. QNCX is outperformed by 85.52% of its industry peers.
- QNCX has a Quick Ratio of 1.12. This is a normal value and indicates that QNCX is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.12, QNCX is not doing good in the industry: 84.57% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 2.12% over the past year.
EPS 1Y (TTM)2.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 18.46% on average over the next years. This is quite good.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.71%
EPS Next 2Y19.19%
EPS Next 3Y15.06%
EPS Next 5Y18.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for QNCX. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QNCX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as QNCX's earnings are expected to grow with 15.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.19%
EPS Next 3Y15.06%
5. Dividend
5.1 Amount
- QNCX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
QUINCE THERAPEUTICS INC / QNCX FAQ
Can you provide the ChartMill fundamental rating for QUINCE THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 1 / 10 to QNCX.
What is the valuation status for QNCX stock?
ChartMill assigns a valuation rating of 0 / 10 to QUINCE THERAPEUTICS INC (QNCX). This can be considered as Overvalued.
What is the profitability of QNCX stock?
QUINCE THERAPEUTICS INC (QNCX) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for QNCX stock?
The Earnings per Share (EPS) of QUINCE THERAPEUTICS INC (QNCX) is expected to grow by 7.71% in the next year.